Entebbe Cohort Summary

Entebbe Cohort Data Summary

Section Title

Description

Source population

HIV-infected adults residing within approximately 40 km of Entebbe and attending designated outpatient HIV clinics.

Study Location

Entebbe, Wakiso District, Uganda.

Study Period

Established in 1995 following completion of a pneumococcal vaccination trial among adults living with HIV and continued as a long-term longitudinal cohort with ongoing follow-up and linked research studies.

Protocol title

Entebbe HIV Cohort Study.

Study design

Prospective open longitudinal cohort study with six-monthly follow-up visits and additional unscheduled visits when participants became ill.

Sponsor/Funder

Medical Research Council (MRC), United Kingdom, and collaborating international research partners supporting various phases of the cohort and associated studies.

Implementing Institution

MRC/UVRI and LSHTM Uganda Research Unit (formerly MRC Programme Uganda).

Background /Rationale

The Entebbe Cohort was established in 1995 following a pneumococcal vaccination trial among adults living with HIV in the Entebbe region. The cohort evolved into a long-term research platform designed to investigate the natural history of HIV infection, determinants of morbidity and mortality, and the effectiveness of interventions aimed at improving the health of people living with HIV. Over time, the cohort has supported numerous studies on HIV disease progression, opportunistic infections, prophylactic interventions, and antiretroviral therapy (ART), generating evidence that has informed HIV treatment guidelines and public health policy in Uganda and across sub-Saharan Africa.

Primary Objective

To investigate HIV disease progression and identify factors associated with morbidity, mortality, and survival among adults living with HIV.

Secondary objectives

Evaluate the effectiveness of preventive and therapeutic interventions, including cotrimoxazole prophylaxis, vaccination, and ART.

Assess immunological and haematological changes during HIV infection and treatment.

Monitor ART initiation and treatment outcomes.

Investigate the epidemiology and outcomes of opportunistic infections.

Generate evidence to improve HIV clinical care and public health programmes.

Specific Aims

Characterize the natural history of HIV infection in a Ugandan population.

Determine predictors of disease progression, morbidity, and mortality.

Evaluate the effectiveness of prophylactic and therapeutic interventions.

Assess outcomes associated with opportunistic infections, including cryptococcal disease.

Monitor immunological, clinical, and treatment-related outcomes over time.

Provide evidence to inform HIV treatment policies and clinical guidelines.

Study Site and infrastructure 

The cohort was conducted through outpatient HIV clinics serving communities around Entebbe. Infrastructure included dedicated clinical facilities, laboratory services, specimen processing and storage systems, and longitudinal database management platforms. Laboratory capacity included HIV diagnostics, CD4+ T-cell testing, haematology, microbiology, blood cultures, and specimen archiving for future research. The cohort benefited from multidisciplinary expertise in epidemiology, clinical research, immunology, microbiology, biostatistics, and public health.

Target Population

Adults aged 15–59 years residing within approximately 40 km of Entebbe and attending participating HIV outpatient clinics.

Eligibility criteria

HIV-positive adults aged 15–59 years residing within the study catchment area and willing to participate in longitudinal follow-up and clinical assessments.

Recruitment and enrollment

Participants were recruited from designated outpatient HIV clinics serving communities in and around Entebbe. The cohort operated as an open cohort, allowing continuous enrolment of eligible participants over time. Cohort size varied throughout the study period because of ongoing enrolment, deaths, transfers, and losses to follow-up.

Follow-up procedures

Participants attended scheduled visits every six months for clinical, immunological, and haematological assessments. Additional unscheduled visits were conducted whenever participants became ill or required medical evaluation. Follow-up included clinical review, treatment monitoring, laboratory investigations, and documentation of morbidity and mortality outcomes.

Data and specimen collection

Data collected included:

·         WHO HIV clinical staging (1993 and 2005 classifications)

·         CD4+ T-cell counts measured using FACSCount technology

·         Haemoglobin and differential white blood cell counts

·         HIV serostatus using dual enzyme immunoassays (EIA) with Western blot confirmation of discordant results

·         Microbiological investigations, including blood cultures and other clinical specimens

·         Vaccination records and prophylactic interventions

·         ART initiation, treatment history, and outcomes

·         Opportunistic infections and clinical events

·         Morbidity and mortality outcomes.

·         Biological specimens included blood and other clinical samples collected for diagnostic and research purposes.

Key findings

·         Demonstrated the feasibility, effectiveness, and safety of cotrimoxazole prophylaxis among adults living with HIV in Uganda.

·         Generated important evidence on cryptococcal infection, cryptococcal antigenaemia, cryptococcal meningitis, and associated mortality among people living with HIV.

·         Documented substantial reductions in morbidity and mortality following initiation of antiretroviral therapy (ART).

·         Identified predictors of mortality among ART-naïve and ART-experienced individuals, including long-term mortality trends in the HAART era.

·         Characterized haematological and immunological changes associated with HIV infection and treatment.

·         Contributed evidence supporting HIV treatment, prevention, and monitoring policies in resource-limited settings.

Impact and publications

The Entebbe Cohort has generated numerous peer-reviewed publications and has contributed substantially to understanding HIV disease progression, opportunistic infections, prophylactic interventions, and ART outcomes in sub-Saharan Africa. Research findings from the cohort have informed national and international HIV treatment guidelines, strengthened evidence-based HIV care programmes, and improved management of opportunistic infections such as cryptococcal disease. The cohort has produced influential publications on cotrimoxazole prophylaxis, cryptococcal infection, ART outcomes, mortality, and HIV-associated morbidity spanning more than two decades of research.

Sub-studies

Pneumococcal Vaccination Trial: The Entebbe Cohort originated from the pneumococcal vaccination trial among adults living with HIV. Long-term follow-up of trial participants established the foundation for the cohort and enabled evaluation of disease progression, morbidity, mortality, and vaccine-related outcomes.

Development of Antiretroviral Therapy in Africa (DART) Trial: A landmark multicentre clinical trial that evaluated monitoring strategies for antiretroviral therapy in resource-limited settings and generated evidence that informed HIV treatment guidelines across Africa.

Cryptococcal Meningitis Study: An observational and clinical study investigating cryptococcal infection, cryptococcal antigenaemia, cryptococcal meningitis, treatment outcomes, and mortality among people living with HIV. This programme contributed substantially to the understanding and management of cryptococcal disease in Uganda and internationally.

Cotrimoxazole Prophylaxis Study: Research evaluating the feasibility, effectiveness, safety, and haematological effects of cotrimoxazole prophylaxis among HIV-infected adults attending HIV clinics in Uganda.